MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES

被引：0
|
作者：
Westerlund, Johanna [1 ]
Jokiranta, T. Sakari [1 ,2 ]
机构：
[1] United Medix Labs Ltd, Espoo, Finland
[2] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2012年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：325 / 325
页数：1
相关论文
共 50 条
  • [21] MEASUREMENT OF TNF-ALPHA DRUG LEVELS AND FREE VERSUS TOTAL ANTI-DRUG ANTIBODIES USING THREE COMMERCIALLY AVAILABLE ASSAYS
    Arkir, Z.
    Unsworth, N.
    Warner, B. D.
    Richards, G.
    Irving, P. M.
    GUT, 2015, 64 : A447 - A448
  • [22] Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis
    Siljehult, F.
    Arlestig, L.
    Eriksson, C.
    Rantapaa-Dahlqvist, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (05) : 345 - 350
  • [23] Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies
    Moneo, Mikel
    del Agua, Ainhoa Ruiz
    Ruiz-Arguello, Begona
    Rapun, Noelia
    Nagore, Daniel
    El Hamss, Rachid
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025,
  • [24] Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases
    Grinman, Ana B.
    de Souza, Maria das Gracas C.
    Bouskela, Eliete
    Carvalho, Ana Teresa P.
    de Souza, Heitor S. P.
    MEDICINE, 2020, 99 (10) : E19359
  • [25] Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
    Marona, Jose
    Rodrigues-Manica, Santiago
    Gomes, Joao Lagoas
    Lopes, Carina
    Iria, Ines
    Bernardes, Miguel
    Santos, Helena
    Tavares-Costa, Jose
    Madruga-Dias, Joao
    Pinto, Patricia
    Bernardo, Alexandra
    Maia, Sara
    Branco, Jaime
    Goncalves, Joao
    Pimentel-Santos, Fernando
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [26] Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
    Karsten, Carley
    Grannas, Karin
    Bergman, Oskar
    Moverare, Robert
    Roforth, Matthew
    Willrich, Maria Alice V.
    Snyder, Melissa R.
    Yang, Yifei K.
    AAPS JOURNAL, 2024, 26 (05):
  • [27] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [28] Tolerating infliximab therapeutic drug monitoring without anti-drug antibodies - an argument for drug intolerant assays?
    Carlson, S.
    Evgeniou, V.
    Kok, K.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 894 - 895
  • [29] Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS™, Infliximab-abda) Using LabCorp Infliximab Assays for Drug Level and Anti-drug Antibodies
    Kelly, Chun
    Zonia, Garcia Gonzalez
    Jane, Yang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S25 - S25
  • [30] Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations
    Kim, J.
    Walshe, M.
    Borowski, K.
    Milgrom, R.
    Stempak, J.
    Lee, S. H.
    Croitoru, K.
    Silverberg, M. S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I933 - I934
12345